Methods of treating fragile X mental retardation syndrome
The invention provides a method of treating FX syndrome and FX premutation by administering an effective amount of a κ-opioid receptor antagonist to an individual having FX syndrome or FX premutation.
1. A method of treating Fragile X syndrome without attention-deficit hyperactivity disorder in an individual in need thereof, the method comprising administering an effective amount of a κ-opioid receptor antagonist to the individual, wherein the κ-opioid receptor antagonist is norbinaltorphimine or CERC-501.
2. The method of claim 1 , wherein the administering reduces the severity of a symptom selected from the group consisting of aggression, impulsivity, social anxiety, repetitive behavior, seizures, impaired social interactions, motor impulsivity, and self-harm.
3. The method of claim 2 , wherein the symptom is social anxiety.
4. The method of claim 2 , wherein the symptom is aggression.
5. The method of claim 2 , wherein the symptom is repetitive behavior.
6. The method of claim 2 , wherein the symptom is impaired social interactions.
7. The method of claim 2 , wherein the symptom is motor impulsivity.
8. The method of claim 1 , wherein the κ-opioid receptor antagonist is CERC-501.
9. The method of claim 1 , wherein the κ-opioid receptor antagonist is norbinaltorphimine.
10. The method of claim 1 , wherein the κ-opioid receptor antagonist is administered for at least one week.
11. The method of claim 1 , wherein the κ-opioid receptor antagonist is administered at a dose of 0.1 to 50 mg/kg.